Seminars in Hematology
Volume 45, Supplement 1 , Pages S3-S6, April 2008

Safety Update on Recombinant Factor VIIa in the Treatment of Congenital and Acquired Hemophilia

  • Thomas Abshire

      Affiliations

    • Corresponding Author InformationAddress correspondence to Thomas Abshire, MD, Aflac Cancer Center and Blood Disorders Service, 2015 Uppergate Dr NE, Room 426 A, Emory University, Atlanta, GA 30322.

Department of Pediatrics, Aflac Cancer Center, and Blood Disorders Service, Emory University and Children's Healthcare of Atlanta, Atlanta, GA.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 STATEMENT OF CONFLICT OF INTEREST: Thomas Abshire is a member of the advisory board for Novo Nordisk.

PII: S0037-1963(08)00046-2

doi:10.1053/j.seminhematol.2008.03.006

Seminars in Hematology
Volume 45, Supplement 1 , Pages S3-S6, April 2008

Article Tools

* Image Usage & Resolution